Reference drugs for triple combination test drug in Russia [Design Issues]
❝ If you look at federal law, you can find:
❝ generic drug - a drug that has the same qualitative composition and quantitative composition of active substances in the same dosage form as the reference drug, and whose bioequivalence or therapeutic equivalence is confirmed by the reference drug with relevant studies.
PharmCat, if we take triple combination e.g. Losartan 100 mg/Amlodipine 5 mg/Rosuvastatin 20 mg (mittyri`s real example) and following reference drugs Losartan 100 mg/Amlodipine 5 mg and Rosuvastatin 20 mg than still the compared drugs have the same qualitative composition and quantitative composition of active substances in the same dosage form as the reference drug as you said. it is still losartan 100 mg whenever you take it.
—
Best regards
Beholder
Best regards
Beholder
Complete thread:
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-13 12:47 [Design Issues]
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-13 21:25
- Reference drugs for triple combination test drug in Russia Yura 2019-11-14 09:24
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-14 10:55
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-14 10:51
- Reference drugs for triple combination test drug in Russia Mikalai 2019-11-15 13:36
- OT: Speak with the regulator Helmut 2019-11-15 13:45
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-15 20:07
- Reference drugs for triple combination test drug in Russia mittyri 2019-11-15 23:29
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-16 17:22
- Reference drugs for triple combination test drug in RussiaBeholder 2019-11-18 10:13
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-18 22:47
- WHO FDC Scenario 2 mittyri 2019-11-19 09:25
- WHO FDC Scenario 2 PharmCat 2019-11-19 23:42
- EEU FDC Scenario 5.3.2 mittyri 2019-11-20 11:32
- EEU FDC Scenario 5.3.2 PharmCat 2019-11-20 15:39
- EMA example mittyri 2019-11-21 12:38
- EEU FDC Scenario 5.3.2 PharmCat 2019-11-20 15:39
- EEU FDC Scenario 5.3.2 mittyri 2019-11-20 11:32
- WHO FDC Scenario 2 PharmCat 2019-11-19 23:42
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-19 14:39
- Reference drugs for triple combination test drug in Russia Yura 2019-11-19 21:51
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-21 14:02
- Reference drugs for triple combination test drug in Russia Yura 2019-11-19 21:51
- WHO FDC Scenario 2 mittyri 2019-11-19 09:25
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-18 22:47
- Reference drugs for triple combination test drug in Russia mittyri 2019-11-15 23:29
- Reference drugs for triple combination test drug in Russia Mikalai 2019-11-15 13:36
- Reference drugs for triple combination test drug in Russia Yura 2019-11-14 09:24
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-13 21:25